PINELOPI KOUKI

Dr. PINELOPI KOUKI

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
NKNikoleta Koliou
Nikoleta Koliou
LKLazaros Kourtidis
Lazaros Kourtidis
PLPanagis M. Lykoudis
Panagis M. Lykoudis
IKIoannis and kapodistrian university of Karavolias
Ioannis and kapodistrian university of Karavolias
SCStavriana Charalampous
Stavriana Charalampous
CIChristos A. Iordanou
Christos A. Iordanou
Background: Artificial intelligence (AI) and large language models (LLMs) may make surgical information easier to access and understand. However, these tools cannot replace the clinician’s role in shared decision-making or the requirements for valid informed consent. Methods: This narrative review follows the surgical patient pathway from diagnosis and explanation to option comparison, shared decision-making, and informed consent. It examines conventional digital tools, LLM-assisted communication, personalized prediction, direct consent studies, patient and professional perspectives and legal, ethical, and governance issues. A formal meta-analysis and study-level risk-of-bias assessment were not performed. Results: AI may support several stages of surgical care. Diagnostic and predictive systems can assist clinicians. LLMs can help explain approved information, prepare patients for consultation, and improve consent materials. Conventional interactive tools have the strongest evidence for better comprehension. Evidence for LLM-assisted consent is still based mainly on simulations and document analyses. Patient-facing use requires source control, privacy protection, and visible clinical oversight. AI cannot establish capacity, voluntariness, or final authorization. We propose a five-level framework in which safeguards increase with clinical influence. Conclusions: AI may support the patient’s path from diagnosis to an informed surgical choice when it uses approved information, serves a defined task, and remains under clinical oversight. Current evidence does not support autonomous AI-mediated consent or AI-directed treatment choice. The aim should be a better-informed, preference-sensitive decision, not an automated signature.

Verified
Journal Article
Open access
PDF file
ATAnna Theodorou-Kanakari
Anna Theodorou-Kanakari
SKStyliani Karathanasi
Styliani Karathanasi
PLPanagis M. Lykoudis
Panagis M. Lykoudis
Martina RekatsinaMartina Rekatsina
Martina Rekatsina
ELEleftheria Lelekaki
Eleftheria Lelekaki
PKPINELOPI KOUKI
PINELOPI KOUKI
Background/Objectives: Subarachnoid anaesthesia is widely preferred for caesarean delivery due to its rapid onset, reliability, and safety. The addition of adjuvants to intrathecal hyperbaric bupivacaine has been shown to enhance the quality of anaesthesia and prolong postoperative analgesia. Opioids are among the most frequently used intrathecal adjuvants; however, their administration is associated with adverse effects. Nalbuphine, a mixed opioid agonist–antagonist, may be a promising agent for obstetric use due to its favourable pharmacodynamic properties. This study aimed to systematically review and, where feasible, meta-analyse the evidence comparing nalbuphine with other intrathecal opioid adjuvants to hyperbaric bupivacaine 0.5% for caesarean section, with a primary focus on efficacy and safety. Methods: A systematic review and meta-analysis of controlled trials was conducted. Web of Science Core Collection, MEDLINE (PubMed), Scopus, the Library of Congress, and LISTA (EBSCO) were systematically searched to identify eligible studies. Pooled mean difference (MD) and risk ratio (RR) were calculated using random-effects model. Results: Ten studies encompassing 1095 parturients were included. Compared with fentanyl, intrathecal nalbuphine was associated with a modest prolongation of effective analgesia. However, this finding was accompanied by substantial heterogeneity and very low certainty of evidence. In contrast, morphine provided a longer duration of analgesia than nalbuphine. Overall, nalbuphine and fentanyl demonstrated comparable block characteristics, with only minimal and clinically insignificant differences in onset and duration. Importantly, nalbuphine was associated with fewer adverse effects, particularly shivering and PONV. Conclusions: Subarachnoid nalbuphine may serve as a potential alternative adjuvant to 0.5% hyperbaric bupivacaine in caesarean section anaesthesia. It may provide an analgesic efficacy comparable to fentanyl and, although less potent than morphine, it may demonstrate a more favourable safety profile.